Drug Details
| General Information of the Drug (ID: DR1651) | ||||
|---|---|---|---|---|
| Name |
Buthionine sulfoximine
|
|||
| Synonyms |
BUTHIONINE SULFOXIMINE; 5072-26-4; Buthionine sulphoximine; DL-Buthionine-[S,R]-sulfoximine; Butionine sulfoximine; Buthionine sulfoxamine; D,L-Buthionine-(S,R)-sulfoximine; DL-Buthionine-sulfoximine; Buthionine-S,R-sulfoximine; 2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; 2-Amino-4-(butylsulfonimidoyl)butanoic acid; DL-Buthionine-(S,R)-sulfoximine; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-; CHEBI:28714; DL-butathionine-(S,R)-sulfoximine; MFCD00070309; NSC326231; NSC381100; L-Buthionine-(S,R)-sulfoximine; S-butyl-DL-homocysteine (S,R)-sulfoximine; S-Butyl-DL-homocysteine-[S,R]-sulfoximine; 2-amino-4-(S-butylsulfonimidoyl)butyric acid; NSC 326231; BRN 2367136; Buthione sulfoximine; DL-Buthionine (S,R)-sulfoximine, 99%; 71765-30-5; NSC 381100; DL-Buthionine-S,R-sulfoximine; l-buthionine (s,r)-sulfoximine; dl-buthionine (s,r)-sulfoximine; NSC-381100; BSO; Sulfoximine, S-(3-amino-3-carboxypropyl)-S-butyl-; Lopac0_000231; SCHEMBL62033; BSPBio_002464; SPECTRUM1505108; dl-Buthionine(S,R)-sulfoximine; CHEMBL1256575; CHEMBL1627290; DTXSID6044434; CHEBI:176510; HMS3260P03; BCP24029; BCP27775; Tox21_500231; s2433; STL328818; AKOS022106364; CCG-204326; DB12870; LP00231; MCULE-8178742509; SDCCGSBI-0050219.P003; NCGC00015148-03; NCGC00015148-04; NCGC00015148-05; NCGC00015148-06; NCGC00015148-07; NCGC00015148-13; NCGC00093696-01; NCGC00093696-02; NCGC00093696-03; NCGC00260916-01; AS-67962; NCI60_002827; HY-106376; CS-0025687; EU-0100231; FT-0624379; FT-0627738; FT-0663956; ST51012445; DL-Buthionine-sulfoximine, >=99.0% (TLC); 2-Amino-4-(butylsulfonimidoyl)butanoic acid #; B 2640; C04543; SR-01000075713; Q5002519; SR-01000075713-1; 2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid; BRD-A04020513-001-01-9; D,L-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Malaria [ICD-11: 1F40] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C8H18N2O3S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCCCS(=N)(=O)CCC(C(=O)O)N
|
|||
| InChI |
1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)
|
|||
| InChIKey |
KJQFBVYMGADDTQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 5072-26-4
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Namalwa | CVCL_0067 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Buthionine Sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Glutamate-cysteine ligase modifier (GCLM) | Molecule Info | [1] | |
| KEGG Pathway | Glutathione metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| Pathwhiz Pathway | Glutamate Metabolism | Click to Show/Hide | ||
| 2 | Glutathione Metabolism | |||
| 3 | Cysteine Metabolism | |||
| WikiPathways | Transcriptional activation by NRF2 | Click to Show/Hide | ||
| 2 | NRF2 pathway | |||
| 3 | Nuclear Receptors Meta-Pathway | |||
| 4 | Metabolism of amino acids and derivatives | |||
| 5 | Trans-sulfuration and one carbon metabolism | |||
| 6 | Trans-sulfuration pathway | |||
| 7 | Phase II conjugation | |||
| 8 | Glutathione metabolism | |||
